• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Syniverse Holdings

Syniverse Holdings

Putnam AZ Tax Exempt Income B PAZBX 2 Star

Last Price$9.02Day Change (%)0.00%
Open Price$9.02Day Change ($)0.00
Day Range9.02–9.0252-Week Range8.87–9.45

As of Thu 04/27/2017 | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. China FDA Approves Country’s First All-Oral Regimen for Chronic Hepatitis C, Daklinza® (daclatasvir) in Combination with Sunvepra® (asunaprevir)

    China FDA Approves Country’s First All-Oral Regimen for Chronic Hepatitis C, Daklinza® (daclatasvir) in Combination with Sunvepra® (asunaprevir)

  2. Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with ...

    Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C

  3. Enanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir ...

    Enanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)

  4. Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C

    Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C

  5. Raining Liquidity on the ‘Ticker Tape-r’ Parade

    Syniverse Holdings SVR posted second-quarter results that mostly met our expectations. We are reiterating our opinion that this company has very little growth potential and no competitive advantage. We continue to be less than positive on the overall market for providing network services to ...

  6. Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2017

    Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2017

  7. March's Stock Red Flags

    Three stocks we think investors should be wary of.

©2017 Morningstar Advisor. All right reserved.